Histogen, Inc.
(NASDAQ : CNAT)

( )
CNAT PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.86%156.270.0%$4727.15m
NVAXNovavax, Inc. 0.17%129.3892.9%$693.33m
BIIBBiogen, Inc. 0.37%245.001.7%$660.08m
BNTXBioNTech SE -0.90%117.610.0%$650.39m
AMGNAmgen, Inc. -0.39%226.021.3%$590.64m
GILDGilead Sciences, Inc. 0.15%60.951.0%$519.07m
VRTXVertex Pharmaceuticals, Inc. 0.94%229.001.9%$490.00m
REGNRegeneron Pharmaceuticals, Inc. 0.49%501.302.7%$485.35m
ILMNIllumina, Inc. 0.15%346.503.5%$429.07m
EXASEXACT Sciences Corp. 1.02%132.0019.6%$201.33m
APVOAptevo Therapeutics, Inc. -0.20%45.9018.3%$174.08m
SGENSeagen Inc. 0.00%180.165.8%$171.25m
ALXNAlexion Pharmaceuticals, Inc. 0.00%121.062.0%$141.98m
BGNEBeiGene Ltd. 0.43%222.251.4%$136.23m
SRNESorrento Therapeutics, Inc. -0.13%7.961.4%$135.59m

Company Profile

Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA.